ALA Shares Arovella Therapeutics Limited
ASX · ASXLast in our picks 2026-10-15 — not in the current list; analysis below is from that screen
Cell-therapy platform targets high-value oncology indications with potential clinical inflection points.
Future value: $0.09 (+80.00%) · 6-12 months
Signal breakdown
- ▸Clinical pipeline provides upcoming value inflection potential.
- ▾Below 50-day MA (-13.27%)
- ▸Volume 2.52× average — accumulation
- ▾Near 52-week low (7.4% of range)
- ▸~80% upside to price target
Is ALA a buy right now?
Trend: ALA is trading below the 50-day average (-18.33%), RSI 24 — oversold territory, with a 3-month return of -18.33%.
Valuation & quality: Arovella Therapeutics Limited trades on forward P/E -4.9, price-to-book 4.08; fundamentals show net margin -197.7%, return on equity -40.4%, revenue growth 34746.3% year on year.
Our screen: BUY (score 2) — Cell-therapy platform targets high-value oncology indications with potential clinical inflection points.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -12.50% | +14.30% | -12.50% | -14.30% | +0.00% | +0.00% | -16.70% | +0.00% |
Fundamentals
Technical signals
About Arovella Therapeutics Limited
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.